04/08/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.55 million subscribed by a limited number of investors Download PDF Post navigationPreviousPrevious post:AB Science receives regulatory approval from european countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AMLNextNext post:AB Science announces a slight delay in the publication of its 2025 half-year financial reportRelated PostsAB Science announces the successful completion of a 2.8 million euros private placementOctober 17, 2025Summary of the virtual conference held on October 16, 2025October 16, 2025AB Science webcast of October 16, 2025October 16, 2025AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939October 14, 2025Revenues for the first half of 2025 and update on AB Science’s activitiesOctober 10, 2025AB Science announces a slight delay in the publication of its 2025 half-year financial reportSeptember 30, 2025
AB Science announces the successful completion of a 2.8 million euros private placementOctober 17, 2025
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939October 14, 2025
AB Science announces a slight delay in the publication of its 2025 half-year financial reportSeptember 30, 2025
